Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis

Fig. 1

Summary of the primary efficacy outcome. A Network plot of change in MMDs. The width of the lines is proportional to the number of studies comparing every pair of treatments, and the size of each circle is proportional to the number of participants. B The forest plot shows the risk ratio (RR) and credible interval (CrI). C Ranking probabilities graph (blue bars) of each treatment agent. The SUCRA values (red bars) for each treatment are as follows: 84% for galcanezumab 240 mg; 76% for monthly fremanezumab; 66% for eptinezumab 300 mg; 61% for galcanezumab 120 mg; 60% for quarterly fremanezumab; 47% for eptinezumab 100 mg; 30% for erenumab 140 mg; 24% for erenumab 70 mg; 2% for placebo. MMDs: monthly migraine days; SUCRA: surface under the cumulative ranking curve

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us